An experimental cystic fibrosis treatment with South Canterbury links will start the next phase of its trial in 2016.
Breathe Easy is seeking participants for an initial efficacy trial of its Citramel formula after completing its safety trial in Christchurch.
The company’s scientific advisory board chairman, Dr. Paul Tan, said on Tuesday the Christchurch trial had revealed no safety concerns about the nebulizing liquid, which is designed to dissolve biofilms on the mucus which coats the lungs of people with cystic fibrosis.
Researchers conducting the first trial used healthy subjects. Tan said the company now aimed to recruit about 24 people with cystic fibrosis to try the drug.